Cases
Workhorse listing across all UPC cases. Filters apply across tabs.
| Date | Case | Division | Action | Motion | Outcome | Summary |
|---|---|---|---|---|---|---|
| 2025-07-31 | UPC_CFI_382/2025 | Milan CD | Application For Costs | — | Costs only | Decision on costs from the Milan Central Division dated 31 July 2025 in proceedings where Novartis AG sought reimbursement of costs from Zentiva K.S. and Zentiva Portugal Lda following the dismissal of Zentiva's revocation action against EP 2 501 384. The court dismissed Novartis' costs application because Novartis failed to comply with the court's request under R. 156.1 RoP to provide substantiated evidence of costs (itemised hourly rates and hours), instead providing only a sworn general statement. The court held that: (1) once a R. 156.1 request is issued, costs can no longer be assessed equitably but only on proof; (2) confidentiality cannot be invoked to withhold cost information from the court; (3) costs for legal representation are not per se confidential under R. 262A RoP. |
| 2025-04-10 | UPC_APP_10151/2025 | Milan CD | Application RoP262.1 (b) | Procedural | Procedural only | The Milan Central Division granted ALIUD PHARMA's application for access to pleadings filed in closed proceedings between Accord Healthcare and Novartis (EP 2 501 384) under R. 262.1(b) RoP, after Novartis withdrew its objection following settlement of the main proceedings. |
| 2025-02-03 | UPC_APP_68658/2024 | Milan CD | Application RoP262.1 (b) | Procedural | Dismissed | Application by STADAPHARM GmbH for public access to case documents under R.262.1(b) RoP (separate application number for the same underlying proceedings UPC_CFI_698/2024, Milan Central Division). Outcome identical to companion order: STADAPHARM's request to access documents was dismissed; NOVARTIS's request for legal cost compensation was dismissed. This appears to be the same decision issued under a different application reference number. |
| 2025-02-03 | UPC_CFI_698/2024 | Milan CD | Application RoP262.1 (b) | Procedural | Dismissed | Application by STADAPHARM GmbH for public access to case documents under R.262.1(b) RoP in the proceedings before the Milan Central Division was dismissed. The court found that STADAPHARM's primary purpose was to expose Novartis's defence strategy in order to facilitate a parallel national (Munich OLG) proceeding rather than to exercise legitimate public oversight. Access was denied as it would create undue pressure on Novartis and undermine the integrity of the proceedings. NOVARTIS's request for costs was also dismissed. |